Tizona develops oncology drugs, which Gilead said will help it boost its immuno-oncology pipeline.
Under the deal, Gilead has the option to acquire the rest of the company for $1.25 billion. Gilead can wait to acquire the rest of the company until Tizona completes a clinical trial of one of its experimental drugs, or it can acquire the company earlier, according to a news release.
The companies said it expects the transaction to close in the third quarter of this year, subject to antitrust approval.
Read Gilead’s full news release here.
More articles on pharmacy:
Fresenius Kabi recalls sedative, cites possible cross-contamination
Biogen CFO steps down
‘Enough is enough’: APhA CEO calls for pharmacy reimbursement overhaul
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.